The National Wilms’ Tumor Study: A Progress Report
Wilms’ tumor was virtually incurable before pediatric surgeons, notably Ladd1, perfected their surgical techniques. Steady improvements thereafter added radiation therapy2 and chemotherapy. The routine postoperative use of actinomycin-D, as reported by Farber3, produced a two-year survival rate of 81% in patients managed from the outset by an experienced team using combination therapy. Wolff and his colleagues4 demonstrated the value of cyclic actinomycin-D given over a prolonged period after operation, and otherss 5,6 showed that vincristine sulfate was effective in the management of these children.
KeywordsTumor Study Vincristine Sulfate Pediatric Acute Leukemia Acute Leukemia Group Combine Patient Population
Unable to display preview. Download preview PDF.
- 3.FARBER, S.: Chemotherapy in the treatment of leukemia and Wilms’ tumor. JAMA, 198: 826, 1966.Google Scholar
- 5.SULLIVAN, M. P., SUTOW, W. W., CANGIR, A. and TAYLOR, G.: Vincristine sulfate in management of Wilms’ tumor. JAMA, 202: 381, 1967.Google Scholar
- 7.VAETH, J. M., ed.: Frontiers of Radiation Therapy and Oncology — Radiation Effect and Tolerance. Normal Tissue. Vol. 6, S. Karger, Basel, Switzerland, 1972.Google Scholar
- 8.SCHNEIDER, M.: Renal embryoma. In: Progress in Radiation Therapy, edited by F. Buschke, Grune & Stratton, New York, 1958, p. 180.Google Scholar
- 9.D’ANGIO, G. J., BECKWITH, J. B., BISHOP, H. C., BRESLOW, N., EVANS, A. E., GOODWIN, W., KING, L. R., PICKETT, L. K., SINKS, L., SUTOW, W. W. and WOLFF, J. A.: The National Wilms’ Tumor Study: A Progress Report. Cancer. (In press)Google Scholar